<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347307</url>
  </required_header>
  <id_info>
    <org_study_id>08-044</org_study_id>
    <nct_id>NCT01347307</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy for Spine Tumors</brief_title>
  <official_title>Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Spine Metastases and Primary Spine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the local control rate as well as acute and late toxicity rates of
      stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine
      tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single site, non-randomized, prospective, phase IV trial. Patients are
      composed of 2 groups:Spine Metastases OR Benign Spine Tumors. Data collected will include
      patient demographics, pathology data, tumor stage, SBRT dose fractionation scheme, dose
      received by adjacent critical normal tissues, tumor recurrence data, and acute and late
      toxicities.

      Follow up data will be collected during the patient's standard office visits. The anticipated
      duration of this study is 5 years
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2008</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial Symptom Control</measure>
    <time_frame>6 weeks post-SBRT (or at first post-treatment follow-up)</time_frame>
    <description>Evaluation of pain relief per patient report</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tumor Recurrence Rate</measure>
    <time_frame>(1) At 1 year post-SBRT, (2) At patient's last follow-up or time of death</time_frame>
    <description>Local recurrence is defined as tumor recurrence or progression within the planning target volume.
Local control rate will be evaluated by imaging techniques and/or clinical symptoms (worsening or no improvement in pain or neurologic compromise). If follow-up imaging is available, a local recurrence will be defined as an increase of &gt; 20% in tumor size.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Toxicity Rate</measure>
    <time_frame>at patient's last follow-up (at least 3 months from treatment) or time of death</time_frame>
    <description>Toxicity will be assessed using CTCAE grading criteria at specified timepoints.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Spinal Metastases</condition>
  <condition>Vertebral Metastases</condition>
  <condition>Benign Spinal Tumors</condition>
  <condition>Chordoma</condition>
  <condition>Meningioma</condition>
  <condition>Schwannoma</condition>
  <condition>Neurofibroma</condition>
  <condition>Paragangliomas</condition>
  <condition>Arteriovenous Malformations</condition>
  <arm_group>
    <arm_group_label>SBRT for Benign Extradural Spine Tumors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT for Vertebral/Paraspinal Metastases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT for Benign Extradural Spine Tumors</intervention_name>
    <description>14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
    <arm_group_label>SBRT for Benign Extradural Spine Tumors</arm_group_label>
    <other_name>Stereotactic Body Radiotherapy (SBRT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT for Vertebral/Paraspinal Metastases</intervention_name>
    <description>12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
    <arm_group_label>SBRT for Vertebral/Paraspinal Metastases</arm_group_label>
    <other_name>Stereotactic Body Radiotherapy (SBRT)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          -  Patient age &gt;= 18 years

          -  performance status of 0-3

          -  Vertebral and/or paraspinal metastases, with or without prior surgery and/or
             fractionated radiotherapy

          -  Benign extradural spine tumors such as chordomas, meningiomas, schwannomas,
             neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).

          -  Established histologic diagnosis of a benign or malignant tumor of the spine.

          -  Arteriovenous malformation of the spine identified radiographically (no biopsy)

          -  Well-defined lesion involving no more than 2 adjacent vertebral levels or spinal
             segment

          -  Minimal spinal canal compromise that is not rapidly progressive. Ideally, the tumor
             should not be within 5 mm of the spinal cord.

          -  If chemotherapy is planned, ideally it should not have been given within 30 days of
             starting radiation and should not resume until at least 2 weeks after completing
             radiation. In addition, it is not recommended to perform SBRT when targeted
             anti-angiogenesis therapy is planned within 2 months of the procedure.

          -  Signed study-specific consent form

        Exclusion Criteria:

          -  Lesion involving &gt; 3 adjacent vertebral levels

          -  Overt spinal instability

          -  Neurologic deficit due to bony fragments/bony compression of neural structures

          -  Prior radiotherapy at the involved level(s) within 3 months of radiosurgery, more than
             one prior course of radiotherapy at the involved level(s), or more than 45 Gy previous
             radiation exposure at the involved level(s)

          -  Rapidly progressive spinal cord compromise or neurological deficit

          -  Paralysis, or otherwise compromised motor function due to radiographically confirmed
             cord compression

          -  Patient unable to undergo an MRI

          -  Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown
             effects of RT on lactating females

          -  Patients with psychiatric or addictive disorder that would preclude obtaining informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bethany Sleckman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mercy Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy Medical Center, St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>February 19, 2019</results_first_submitted>
  <results_first_submitted_qc>June 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2020</results_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Research</investigator_affiliation>
    <investigator_full_name>Juli Mai, MD</investigator_full_name>
    <investigator_title>Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>stereotactic radiotherapy</keyword>
  <keyword>spinal metastases</keyword>
  <keyword>vertebral metastases</keyword>
  <keyword>benign spinal tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Chordoma</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
    <mesh_term>Spinal Neoplasms</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 4, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT01347307/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SBRT for Benign Extradural Spine Tumors</title>
          <description>Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
Stereotactic Body Radiation Therapy (SBRT) for Benign Extradural Spine Tumors: 14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
        </group>
        <group group_id="P2">
          <title>SBRT for Vertebral/Paraspinal Metastases</title>
          <description>Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
SBRT for Vertebral/Paraspinal Metastases: 12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>2 enrolled patients were not treated. 35 patients completed 36 Stereotactic Body Radiotherapy courses for a total of 38 patients included at baseline.</population>
      <group_list>
        <group group_id="B1">
          <title>SBRT for Benign Extradural Spine Tumors</title>
          <description>Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
SBRT for Benign Extradural Spine Tumors: 14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
        </group>
        <group group_id="B2">
          <title>SBRT for Vertebral/Paraspinal Metastases</title>
          <description>Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
SBRT for Vertebral/Paraspinal Metastases: 12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age Range</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="55" upper_limit="82"/>
                    <measurement group_id="B2" value="62" lower_limit="34" upper_limit="90"/>
                    <measurement group_id="B3" value="62" lower_limit="34" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Caucasion</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Initial Symptom Control</title>
        <description>Evaluation of pain relief per patient report</description>
        <time_frame>6 weeks post-SBRT (or at first post-treatment follow-up)</time_frame>
        <population>2 enrolled pts were not treated. 35 pts completed 36 SBRT courses. 5 pts either died prior to any follow-up appointment or imaging (4 pts) or did not follow-up due to loss of insurance (1 pt). 3 pts with benign spine tumors and 28 pts with vertebral metastases who underwent a total of 32 courses of SBRT had follow-up data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>SBRT for Benign Extradural Spine Tumors</title>
            <description>Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
SBRT for Benign Extradural Spine Tumors: 14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
          </group>
          <group group_id="O2">
            <title>SBRT for Vertebral/Paraspinal Metastases</title>
            <description>Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
SBRT for Vertebral/Paraspinal Metastases: 12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Symptom Control</title>
          <description>Evaluation of pain relief per patient report</description>
          <population>2 enrolled pts were not treated. 35 pts completed 36 SBRT courses. 5 pts either died prior to any follow-up appointment or imaging (4 pts) or did not follow-up due to loss of insurance (1 pt). 3 pts with benign spine tumors and 28 pts with vertebral metastases who underwent a total of 32 courses of SBRT had follow-up data available for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with Follow-up Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number with Initial Symptom Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number without Symptom Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Local Tumor Recurrence Rate</title>
        <description>Local recurrence is defined as tumor recurrence or progression within the planning target volume.
Local control rate will be evaluated by imaging techniques and/or clinical symptoms (worsening or no improvement in pain or neurologic compromise). If follow-up imaging is available, a local recurrence will be defined as an increase of &gt; 20% in tumor size.</description>
        <time_frame>(1) At 1 year post-SBRT, (2) At patient's last follow-up or time of death</time_frame>
        <population>35 pts completed 36 SBRT courses. All 3 benign tumor pts are still alive. 15 pts with metastatic disease died prior to first post-SBRT follow-up appointment or imaging (4 pts), did not follow-up due to loss of insurance (1 pt), or had initial follow-up but then died prior to 1 year from treatment completion (10 pts).</population>
        <group_list>
          <group group_id="O1">
            <title>SBRT for Benign Extradural Spine Tumors</title>
            <description>Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
SBRT for Benign Extradural Spine Tumors: 14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
          </group>
          <group group_id="O2">
            <title>SBRT for Vertebral/Paraspinal Metastases</title>
            <description>Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
SBRT for Vertebral/Paraspinal Metastases: 12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
          </group>
        </group_list>
        <measure>
          <title>Local Tumor Recurrence Rate</title>
          <description>Local recurrence is defined as tumor recurrence or progression within the planning target volume.
Local control rate will be evaluated by imaging techniques and/or clinical symptoms (worsening or no improvement in pain or neurologic compromise). If follow-up imaging is available, a local recurrence will be defined as an increase of &gt; 20% in tumor size.</description>
          <population>35 pts completed 36 SBRT courses. All 3 benign tumor pts are still alive. 15 pts with metastatic disease died prior to first post-SBRT follow-up appointment or imaging (4 pts), did not follow-up due to loss of insurance (1 pt), or had initial follow-up but then died prior to 1 year from treatment completion (10 pts).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local Control at last Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response to Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Recurrence after Initial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number with at least 1 year Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Control at 1 year Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Recurrence within 1st year of Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Toxicity Rate</title>
        <description>Toxicity will be assessed using CTCAE grading criteria at specified timepoints.</description>
        <time_frame>at patient's last follow-up (at least 3 months from treatment) or time of death</time_frame>
        <population>2 enrolled pts were not treated. 35 pts completed 36 SBRT courses. 5 pts either died prior to any follow-up appointment or imaging (4 pts) or did not follow-up due to loss of insurance (1 pt). 3 pts with benign spine tumors and 28 pts with vertebral metastases who underwent a total of 32 courses of SBRT had follow-up data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>SBRT for Benign Extradural Spine Tumors</title>
            <description>Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
SBRT for Benign Extradural Spine Tumors: 14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
          </group>
          <group group_id="O2">
            <title>SBRT for Vertebral/Paraspinal Metastases</title>
            <description>Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
SBRT for Vertebral/Paraspinal Metastases: 12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
          </group>
        </group_list>
        <measure>
          <title>Late Toxicity Rate</title>
          <description>Toxicity will be assessed using CTCAE grading criteria at specified timepoints.</description>
          <population>2 enrolled pts were not treated. 35 pts completed 36 SBRT courses. 5 pts either died prior to any follow-up appointment or imaging (4 pts) or did not follow-up due to loss of insurance (1 pt). 3 pts with benign spine tumors and 28 pts with vertebral metastases who underwent a total of 32 courses of SBRT had follow-up data available for analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were followed until time of death or until lost to follow-up.</time_frame>
      <desc>Serious adverse events are defined as events that result in either death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Events not meeting this definition are listed under Other Adverse Events (not serious). Only 28 of the patients within the metastases arm had follow-up data collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>SBRT for Benign Extradural Spine Tumors</title>
          <description>Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
SBRT for Benign Extradural Spine Tumors: 14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
        </group>
        <group group_id="E2">
          <title>SBRT for Vertebral/Paraspinal Metastases</title>
          <description>Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
SBRT for Vertebral/Paraspinal Metastases: 12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophagitis</sub_title>
                <description>Esophagitis requiring management with triple mix (Benadryl/Maalox/Lidocaine), oral steroids, Vicodin, and a soft diet, and resulted in &lt; 10 pound weight loss.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Self limiting nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>mild esophagitis</sub_title>
                <description>esophagitis lasting less than 7 days, not interfering with eating, no or minimal intervention required</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle pain</sub_title>
                <description>temporary increased pain at treated site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>desquamation</sub_title>
                <description>skin redness and peeling</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lead Regulatory Coordinator - Investigator Initiated Trials</name_or_title>
      <organization>Mercy Research</organization>
      <phone>314-251-8827</phone>
      <email>michelle.mcfarland@mercy.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

